NasdaqGS - Nasdaq Real Time Price USD

Amedisys, Inc. (AMED)

91.05

-0.11

(-0.12%)

At close: 4:00 PM EDT

90.78

-0.27

(-0.30%)

After hours: 4:45 PM EDT

Amedisys Reports First Quarter 2024 Financial Results

BATON ROUGE, La., April 24, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period ended March 31, 2024. Three-Month Periods Ended March 31, 2024 and 2023 Net service revenue increased $15.0 million to $571.4 million compared to $556.4 million in 2023. Prior year included $15.0 million of net service revenue from our personal care business which was divested on March 31, 2023.Net income attributable to Amedisys, Inc. of $14.4 millio

GlobeNewswire 2 hours ago

AMED
-0.12%
Amedisys (AMED) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Amedisys (AMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 9 hours ago

AMED
-0.12%
Here's Why Amedisys (AMED) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks yesterday

AMED
-0.12%
Why Amedisys (AMED) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks 30 days ago

AMED
-0.12%
Why Is Amedisys (AMED) Down 2.5% Since Last Earnings Report?

Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks last month

AMED
-0.12%
EHC
+0.41%
How Amedisys (AMED) Stock Stands Out in a Strong Industry

Amedisys (AMED) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks last month

AMED
-0.12%
Oregon's health authority reviewing UnitedHealth's acquisition of Amedisys

UnitedHealth had announced the acquisition in June, after competing with Option Care Health. The acquisition was meant to help expand UnitedHealth's presence in home healthcare, a business it bolstered through a $5.4 billion deal to buy Amedisys' rival, LHC Group, last year.

Reuters last month

UNH

AMED
-0.12%
UPDATE 1-Oregon's health authority reviewing UnitedHealth's acquisition of Amedisys

Amedisys said on Tuesday Oregon's health authority has started a review of UnitedHealth Group's $3.3 billion acquisition of the home health and hospice caregiver. UnitedHealth had announced the acquisition in June, after competing with Option Care Health. The acquisition was meant to help expand UnitedHealth's presence in home healthcare, a business it bolstered through a $5.4 billion deal to buy Amedisys' rival, LHC Group, last year.

Reuters last month

AMED
-0.12%
UNH
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks last month

AMED
-0.12%
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks last month

AMED
-0.12%
Amedisys' (AMED) Q4 Earnings Miss Estimates, Margins Up

The continuous shortage of clinical labor, nursing in particular, is likely to have impacted Amedisys' (AMED) Q4 performance.

Zacks last month

AMED
-0.12%
SYK

CAH
AMED vs. USPH: Which Stock Is the Better Value Option?

AMED vs. USPH: Which Stock Is the Better Value Option?

Zacks 2 months ago

USPH

AMED
-0.12%
Amedisys (AMED) Reports Q4 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Amedisys (AMED) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks 2 months ago

AMED
-0.12%
Amedisys (AMED) Q4 Earnings Lag Estimates

Amedisys (AMED) delivered earnings and revenue surprises of -9.62% and 1.05%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

AMED
-0.12%
CHE
+0.23%
Amedisys Inc (AMED) Reports Mixed Results Amidst Merger Transactions

Net Income Dips While Revenue Grows in Q4 and Full-Year 2023

GuruFocus.com 2 months ago

AMED
-0.12%
Amedisys Reports Fourth Quarter and Year-End 2023 Financial Results

BATON ROUGE, La., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period and year ended December 31, 2023. Three-Month Periods Ended December 31, 2023 and 2022 Net service revenue increased $8.8 million to $570.8 million compared to $562.0 million in 2022. Prior year included $15.9 million of net service revenue from our personal care business which was divested on March 31, 2023.Net income attributable to Amedisys, Inc. of

GlobeNewswire 2 months ago

AMED
-0.12%
Amedisys (AMED) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Amedisys (AMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 2 months ago

AMED
-0.12%
Amedisys Offers Molecular Testing for Rapid and Accurate Infection Diagnosis

BATON ROUGE, La., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and high-acuity care in the home, is now offering advanced molecular testing to its care centers nationwide. This innovative collaboration with Patient Choice Laboratories utilizes molecular testing for the swift and precise identification of pathogens in urine, respiratory and wound infections. By leveraging the latest in diagnostic technology, Amedisys aims to improve t

GlobeNewswire 2 months ago

AMED
-0.12%
20 Most Medically Advanced Countries in the World Heading into 2024

In this article, we’ll take a look at the 20 Most Medically Advanced Countries in the World Heading into 2024. We’ll also deep diver into the medical industry market insights and some key players in the industry. To skip the detailed analysis and see the top 5 countries, read 5 Most Medically Advanced Countries in […]

Insider Monkey 4 months ago

AMED
-0.12%
AMWL

KNCAY
Chemed (CHE) Up 4.8% Since Last Earnings Report: Can It Continue?

Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 4 months ago

CHE
+0.23%
AMED
-0.12%

Performance Overview

Return	AMED	S&P 500
YTD	-4.22%	+6.33%
1-Year	+15.62%	+22.70%
3-Year	-68.00%	+21.33%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Amedisys, Inc. (AMED)

Amedisys Reports First Quarter 2024 Financial Results

Amedisys (AMED) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Here's Why Amedisys (AMED) is a Strong Value Stock

Why Amedisys (AMED) is a Top Value Stock for the Long-Term

Why Is Amedisys (AMED) Down 2.5% Since Last Earnings Report?

How Amedisys (AMED) Stock Stands Out in a Strong Industry

Oregon's health authority reviewing UnitedHealth's acquisition of Amedisys

UPDATE 1-Oregon's health authority reviewing UnitedHealth's acquisition of Amedisys

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Amedisys' (AMED) Q4 Earnings Miss Estimates, Margins Up

AMED vs. USPH: Which Stock Is the Better Value Option?

Amedisys (AMED) Reports Q4 Earnings: What Key Metrics Have to Say

Amedisys (AMED) Q4 Earnings Lag Estimates

Amedisys Inc (AMED) Reports Mixed Results Amidst Merger Transactions

Amedisys Reports Fourth Quarter and Year-End 2023 Financial Results

Amedisys (AMED) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Amedisys Offers Molecular Testing for Rapid and Accurate Infection Diagnosis

20 Most Medically Advanced Countries in the World Heading into 2024

Chemed (CHE) Up 4.8% Since Last Earnings Report: Can It Continue?

Performance Overview